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Abstract 
Premature birth (prior to 37 weeks of gestation) is a big medical and socioeconomic problem. It 
accounts for 8-12% of the total number of births, and apart from causing increased mortality of 
newborns, it is also the cause of increased morbidity.  Fifteen million babies per year are born 
preterm. Despite the frequency, consequences and costs of premature delivery, very little has been 
done for preventing it, especially for preventing extremely premature deliveries (before the 28th 
gestation week). 
Etiology of premature labor is multifactorial, and includes pathophysiology, genetic and 
environmental factors. Recent scientific research shows that genetic factors, mostly present in the 
mother's genome, account for up to 40% of variation in the delivery time. 
It is believed that premature birth exhibits the same cascade of events like a normal birth, only it 
starts sooner. This process is controlled by a series of hormonal effects between the fetus, the 
placenta and the mother. One of the key signaling pathways in this series is the progesterone 
signaling pathway. 
PROGINS allele is a progesterone receptor gene modification. It is made of three variants:  V660L, 
H770H and alu insertion. Progesterone receptors with PROGINS mutation are less susceptible to 
progesterone activity, and it seems that the withdrawal of progesterone causes the beginning of birth 
cascade. Mutation of +331 G/A progesterone receptor is a newly discovered mutation. It is believed 
that this mutation leads to a PR-A and PR-B receptor quantity disorder before the delivery term.  
The aim of this review is to summarize all recent knowledge about PROGINS and +331 G/A mutation 
of progesterone receptors and to estimate whether this genetic mutation has a value in modulation 
of risk of preterm birth. 
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Premature or preterm birth is recognized as a 
worldwide problem. The percentage of preterm 
births has not been reduced despite existing 
research and therapy. It is defined as birth 
between 22nd and 37th week of gestation, and it 
is one of the major causes of prenatal mortality 
and morbidity. Prematurity accounts for 70% of 
neonatal mortality and 75% of neonatal 
morbidity (1). 
According to gestational age, preterm birth is 
divided to extremely preterm birth (between 
24th and 28th week of gestation), early preterm 
(between 28th and 34th week of gestation) and 
late preterm birth (between 34th and 37th week 
of gestation) (2). The percentage of preterm 
births varies from 5% of all deliveries in Europe 
to 18% in South African area (3). There are also 
variations of the percentage of preterm birth in 
diverse ethnical groups; for example, the 
percentage of preterm births is bigger in the 
population of African Americans than in the 
population of Caucasians (4,5).  In 2010, there 
were around 15 million preterm births in the 
world (3,5). In the same period in Croatia, the 
percentage of preterm births was between 5.19 
% and 7.88 % of all births, with a tendency of 
increasing since 2008 (6). 
Etiology and risk factors of preterm delivery 
Etiology of preterm birth is heterogenic and is 
connected to different metabolic pathways in 
the human body. For almost 50 % of preterm 
births, the cause is unknown. Preterm birth is 
divided in three subtypes (2): 
• spontaneous preterm birth 
(spontaneous start of labor); 50% of all 
preterm births, occurring more 
frequently in the population without any 
risk factor for preterm birth 
• preterm premature rupture of 
membranes (PPROM); 25% of all preterm 
births, occurring more often in the 
African-American population, in most 
cases as a result of infection 
• iatrogenic preterm birth before 37 
weeks of gestation, due to maternal or 
fetal medical reasons, or other non-
medical reasons that could jeopardize 
the health of mother and/or fetus (e.g., 
preeclampsia, placenta previa, placental 
abruption, multiple gestation, grow 
restriction of fetus); 25% of all preterm 
births. 
There are many risk factors that relate to 
preterm birth, as indicated in Table 1. In an ideal 
situation, risk factors for preterm birth should be 
identified prior to or during the first trimester of 
pregnancy and, if possible, that should lead to 
interventions which would result in term 
delivery. Some pathways of starting a preterm 
delivery and related risk factors are presented in 
Table 2. 
Nowadays it is more common to use the term 
“preterm parturition syndrome” (7), or even 
“great obstetric syndrome”, because of its 
multifactorial etiology. 
There are four major factors leading to preterm 
labor (7,8,9,86): 1) Pathological uterine 
distension; 2) Maternal fetal stress (premature 
activation of the maternal or fetal hypothalamic-
pituitary adrenal axis); 3) Abruption (decidual 
hemorrhage) and 4) Infection / exaggerated 
inflammatory response. All these processes 
could lead to cervical shortening and could start 
long before obvious signs of preterm birth are 
shown (10). Also, although they start at different 
ends of pathophysiology of preterm birth, they 
end in the same way, by activating 
choriodecidual reaction, uterine contractility and 
changes of the cervix. All these changes lead to 
preterm birth. 
(Kadivnik M, Muller A, Milić Vranješ I, Šijanović S, Wagner J. PROGINS mutation of progesterone 
receptors and its role in premature birth – an overview. SEEMEDJ 2017; 1(2); 55-70) 
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Pathological uterine distension 
It is highly possible that uterine overdistension 
(caused by multifetal pregnancy, 
polyhydramnios or any other cause of uterine 
distension) can cause expression of contraction-
associated proteins (CAPs) in the myometrium. 
Overdistension of the uterus also induces 
formation of gap junctions, upregulates oxytocin 
receptors and produces prostaglandins and 
inflammation cytokines (11). All this can initiate 
events that could change timing of uterine 
activation and lead to uterine contractions and 
cervical dilatation. 
Maternal-fetal stress (premature activation of the 
maternal or fetal hypothalamic-pituitary adrenal 
axis) 
In situations of stress, some circumstances 
disturb normal functions of a person. Maternal 
stress (infection, multiple pregnancies or 
psychological stress, such as depression or 
anxiety) can activate maternal HPA axis and 
cause preterm birth. 
Premature fetal HPA activation, on the other 
hand, can be the result of stress of 
uteroplacental vasculopathy. It is more highly 
correlated with preterm birth than mother’s 
stress (12). The main pathway of this cause 
seems to be a change in fetal adrenal-placental 
endocrine cascade, which leads to early rise of 
maternal CRH (corticotropin-releasing hormone) 
and estrogen levels. CRH plays a role both in 
term and preterm birth. Usually it is released by 
the hypothalamus, but during pregnancy it is 
released by trophoblast and decidual cells, too 
(13,14). Increased production of placental CRH 
stimulates production of ACTH, which further 
Table 1. Etiological risk factors associated with clinical presentation of preterm birth (2). 
Medically induced preterm 
birth 
PPROM (Preterm premature rupture of 
membranes) 
Spontaneous preterm birth 
Maternal factors 
Gestational hypertension and 
vascular disorder 
Acute illness or chronic condition 
Obstetrical complication 
Antepartum bleeding 
Maternal age > 35 years 
Fetal factors 
Intrauterine growth restriction 








Previous preterm birth 
Low body mass, poor weight 
gain 












Table 2. Causes and pathological pathways of preterm birth 
(7) 
• Uterine distension 
• Ischemia 
• Infection 
• Cervical disease 
• Abnormal allograft reaction 
• Allergic phenomena 
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stimulates production of cortisol. Cortisol inhibits 
hypothalamic CRH and ACTH, but on the other 
hand, stimulates CRH from the placenta. CRH 
also induces production of prostaglandins in the 
placenta (15). The increase of prostaglandins 
results in parturition through elevation of 
proteases in the genital tract (e.g., MMP) and 
higher myometrial contractility (16). Also, 
prostaglandins influence the PR-A: PR-B ratio 
and induce functional progesterone withdrawal 
(17). 
Stress, maternal and/or fetal, can also stimulate 
steroid-induced immunophilin cochaperone 
FKBP51 in the decidua. It can also cause 
functional progesterone withdrawal through 
inhibition of progesterone receptors (18). 
One more pathway of preterm birth caused by 
activation of fetal HPA axis is the estrogen 
pathway. Fetal ACTH induces synthesis of DHEA. 
DHEA in fetal liver is converted to 16-hydroxy-
DHEA-S. The placenta converts these 
precursors to E, E2 and E3, which further activate 
the myometrium through increase of gap 
junction formations, oxytocin receptors, activity 
of prostaglandins and increasing of enzymes 
responsible for myometrium contractions (e.g., 
calmodulin) (19,20). All the pathways mentioned 
above cause contractions of the myometrium 
and the start of labor. 
Infection / exaggerated inflammatory response 
It is the only evidence-based and proven cause 
of preterm birth, which activates different 
pathways leading to preterm birth. Infection 
activates a cascade in the immunological 
response of the mother and leads to preterm 
birth. Inflammation is a coordinated process, and 
its role is basically to protect the host. In a normal 
situation, when the immune system is properly 
controlled, inflammation is protective. In other 
cases, it is harmful. 
Preterm birth can be caused by both systemic 
and local genitourinary pathogens. In most 
cases, the cause can be symptomatic or 
asymptomatic bacteriuria (21), presence of 
genital infections (22), periodontal disease (23) 
and clinical and subclinical chorioamnionitis. The 
last-mentioned infection is the cause of as much 
as 50 percent of preterm births before 30 weeks 
of gestation (24). 
Studies have proven that the actual cause of 
preterm birth is not the infection itself but rather 
a disorder of maternal immunity (21-24). 
Pathways of preterm birth in infection start by 
binding of bacterial ligands to toll-like receptors 
(TLRs) in placental, decidual, amniochorion and 
cervical cells. TLRs and local leucocytes activate 
NFkappaB, which in turn, starts the maternal 
and/or fetal inflammatory response. Whether 
TLRs will start the activation of NFkappaB or not, 
depends on the presence of some intracellular 
signaling adaptors (e.g., MyD88), coreceptor 
molecules (e.g., CD 14) and receptor modulators 
(soluble IL 6 receptor, soluble TNF receptor -1, 
etc.) (25-27). 
Activation of NFkappaB leads to activation of 
neutrophils, macrophages and various 
proinflammatory mediators. The most important 
mediators of this response are TNF and IL 1 Beta. 
They induce COX-2 expression and production 
of prostaglandins. TNF also initiates expression 
of various MMPs in the amnion, chorion, decidua 
and cervix, and degrade the matrix of cervix and 
fetal membranes (28,29). TNF alfa can also 
induce apoptosis in amniotic epithelial cells, 
which leads to PPROM. 
Not just the immune response, but some 
bacteria themselves (e.g., Pseudomonas, 
Staphylococcus, Streptococcus) can have a 
direct role in the pathogenesis of preterm birth. 
They can produce enzymes that can degrade 
fetal membranes, as well as phospholipase A2 
and endotoxin, which stimulate uterine 
contractions (30). 
Abruption / decidual hemorrhage 
Vaginal bleeding caused by decidual 
hemorrhage is a risk factor for preterm birth and 
PPROM. According to one study, vaginal 
bleeding lasting more than one trimester 
increases the risk of PPROM seven times (31). 
PPROM develops after decidual hemorrhage, 
due to high concentration of decidual tissue 
factor. It combines with factor VIIa of hemostasis, 
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and in the end, thrombin is generated. Thrombin 
binds to decidual protease-activated receptors, 
which induce expression of proteases (e.g., 
MMP). Abruption can also be related to an 
inflammatory reaction without infection. It starts 
as a result of activation of the immune response 
by free hemoglobin chains and protease. 
Pathological cervical change 
Most cases of cervical changes prior to term 
pertain to cervical insufficiency. The changes 
that cause preterm birth may be the result of a 
congenital disorder, post-surgical trauma or 
damage caused by trauma. In most cases, 
though, cervical shortening is the result of 
inflammatory or hemorrhagic pathways. 
As mentioned above, main changes in preterm 
birth happen on the placental level. They include 
effects on the level of prostaglandins 
(immunology and infection pathways) and the 
endocrine level (progesterone/estrogen 
pathway). Recently, new pathways have been 
identified and they seem to be connected with 
biological and psychosocial factors. These 
pathways include, as mentioned above, 
influence of genetic factors, factors of stress, 
factors that can be attributed to the mother or to 
the fetus, conditions which cause mechanical 
stimuli, and cases of inflammation and infection. 
The role of genes in preterm birth 
Investigations about genetic influence on 
preterm birth have been common during the last 
two decades. Studies have shown that the risk of 
preterm birth is higher in women born 
prematurely. Women who have had a previous 
preterm birth are at greater risk to have it again. 
After the first preterm delivery, the chance of 
another preterm delivery in the same mother 
goes up to 30-50% (32). Also, it has been shown 
that mothers whose sisters, mothers or female 
cousins have had a preterm birth bear greater 
risk of having a similar preterm birth themselves 
(33,34,35). An extensive study, conducted in 
Sweden in 2010, showed that both maternal and 
fetal genes are involved in preterm birth 
(36,37,38).  Fetal genetic factors accounted for 
13.1% of the variation in gestational age at 
delivery, while maternal genetic factors 
accounted for 20.6% (37).  In a similar study, 
estimation of the percent of variation connected 
to fetal genetic factors ranges from 11% to 35%, 
while the range for the maternal genetic 
contribution is 13-20% (39). Another study, by 
Svensson et al., showed that 25% of variation in 
preterm birth was explained by maternal genetic 
effects, 5% by fetal genetic effect, 18% by the 
environment created by the couple and 52% by 
unshared environmental effect (40,41). This and 
other studies showed that paternal genetic 
influence on preterm birth is minimal (up to 5%) 
or there is no influence at all. That fact is in 
discrepancy with two Norwegian studies (42,43). 
In the same study by Svensson et al. it is shown 
that fetal genetic effect is higher if preterm birth 
is induced for medical reasons. Genes can 
influence different pathways in the body 
connected with preterm birth. Most of the 
studies involved gene contribution in 
immunology and inflammation pathways (32,44). 
Induction of proinflammatory mediators, 
especially TNF and its receptors, has been 
suggested to have a crucial role in activation of 
labor, both term and preterm (45). Pro-
inflammatory and anti-inflammatory cytokines 
(interleukins) have also been investigated 
(46,47). There have also been investigations on 
genetic mutations leading to change of uterine 
contractility and change of cervical tissue, which 
leads to cervical shortening and spontaneous 
preterm birth. They involve genetic mutations in 
dopamine receptors, OST receptors, 
progesterone pathway, etc. Recently there have 
been studies about stress influence and genetic 
mutations in preterm birth (48). 
A big genome-wide association study of a large 
cohort of women of European ancestry has 
shown that maternal variants at the EBF1, 
EEFSEC, AGTR2, WNT4, ADCY5, and RAP2C loci 
were associated with gestational duration, and 
that maternal variants at the EBF1, EEFSEC, and 
AGTR2 loci were associated with preterm birth 
(49). 
In this review, the authors will try to see the 
influence of specific genetic polymorphisms 
connected to progesterone pathway that has an 
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important role in maintenance of pregnancy and 
changing contractility of the uterus. 
The role of progesterone in onset of preterm birth 
Progesterone (P4) is one of essential hormones 
in establishing and maintaining pregnancy.  It is 
a 21-carbon steroid hormone which is mainly 
produced in the ovaries, placenta, brain and the 
adrenal glands (50). In early pregnancy, it is 
produced by corpus luteum whereas from 7th 
week of pregnancy onwards, its production 
occurs in the placenta. Progesterone is required 
for maintenance of pregnancy and one can see 
its influence on uterus contractility by inhibition 
of cervical ripening and decreasing of the 
production of chemokines. Progesterone also 
prevents apoptosis in fetal membranes in both 
basal and proinflammatory conditions, and it 
prevents PPROM and, consequently, preterm 
birth (51,52). 
Progesterone produces its physiological effects 
through progesterone receptors (PGRs). PGRs 
are expressed in the central nervous system, 
ovaries, breasts, and the female reproductive 
tracts, including the vagina, cervix, fallopian 
tubes and uterine endometrium and 
myometrium. At term, depending on the 
species, either withdrawal of P4 by a decrease in 
hormone levels or alteration of PGR signaling 
relieves the suppression of inflammation and 
contraction, which allows the myometrium to 
start contractions and lead toward labor.  
Multiple mechanisms, including P4 metabolism, 
regulation of PGR gene expression, PGR post-
translation modifications and PGR co-regulators, 
which mediate or regulate uterine P4/PGR 
signaling, have been identified and reviewed 
(53). One of the hypotheses about preterm birth 
is that the cascade of events in preterm birth is 
similar as the events at term birth, with the 
difference being only that it starts earlier. 
Progesterone receptors are members of the 
group of steroid hormone receptors. They are 
made of central DNA-binding domain (DBD), N-
terminal part with proximal activation function 
(AF1), distal AF3 in B upstream segment, and 
nuclear localization signal which is found 
upstream of LBD. AF1 is ligand-independent, 
while AF is not. AF1 has an influence on direction 
of transcription (54). There are two types of 
progesterone receptors: nuclear and membrane 
receptors (8). The nuclear PRs function as 
ligand-activated transcription factors and they 
influence gene expression. Membrane PRs are 
on the cell surface; they are related to G-protein 
coupled receptors and single transmembrane 
receptors, and they appear to mediate direct 
non-genomic actions of progesterone (8). 
Maintenance of pregnancy is mostly regulated 
through nuclear progesterone receptors, while 
membrane progesterone receptors are less 
sensitive to the influence of progesterone. By 
influencing PRs, progesterone activates a variety 
of pathways and induces expression of other 
genes, which leads to activation or deactivation 
of myometrium. Those pathways include 
activation of certain CAPs (contraction-
associated genes) such as connexin, ion 
channels (e.g., calcium channels), uterotonin 
receptor and enzymes that influence synthesis 
of local prostaglandins (1,55). 
Nuclear receptors are coded by the 
prostaglandin gene located on chromosome 11 
(11q22-q23) (56). Two isoforms of nuclear 
progesterone receptors are most significant for 
progesterone influence; more specifically, PR-A 
and PR-B. Both receptors have the same DNA-
binding domain, ligand-binding domain and 
hinge region. The only difference between these 
two is the fact that there are additional 165 amino 
acids present in the N-terminus of PR-B (18). 
There are some other forms of nuclear PRs 
known, such as PRC, PRM, PRS, PRT etc., but 
their significance in human birth is irrelevant (55). 
PR–B have the function of transcriptional 
activators of genes involved in maintaining 
pregnancy, and PR–A repress the activity of PR-
B.  According to literature, most of the PRs in the 
myometrium during pregnancy are PR-B, and as 
the term of delivery comes nearer, the number 
of PR-A increases (36). 
PR isoforms influence the expression of diverse 
downstream genes through a complex 
regulatory network which includes the NF-κB, 
ZEB-microRNAs and UPR pathways, as well as 
direct transcriptional regulation. They have a 
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combined influence on activities of downstream 
effectors. The overall P4/PGR signaling-
dependent molecular profiles are modified by 
activities of PGR isoforms, co-regulators and the 
ligand availability. P4/PGR signaling mediates 
and utilizes these interconnected pathways to 
determine the state of the myometrium 
throughout pregnancy (53). 
Different influences of PR-A and PR-B isoforms 
are reflected in their influence on expression of 
proinflammatory and anti-inflammatory genes. 
PR-A act proinflammatory, by increasing 
expression of proinflammatory genes for PTGS2, 
IL8, IL1A and PTX3. On the other hand, PR-B 
inhibit expression of proinflammatory genes (57). 
In mammals, it has been proven that birth starts 
at the moment of progesterone withdrawal. 
However, in humans, measurements of the 
levels of serum progesterone in the blood at the 
time of birth showed that there was no 
declination of progesterone level. 
At least five pathways of how withdrawals of 
progesterone influence the start of birth were 
examined. They include: 1) reduced 
bioavailability of progesterone, 2) increased 
cortisol concentration in late pregnancy, which 
leads to progesterone and cortisol competing 
for binding to glucocorticoid receptors (58), 3) 
conversion of progesterone to an inactive form, 
4) changes in isoforms of PG receptors (59), 5) 
changes in progesterone co-regulators (54). 
Some studies also include functional estrogen 
activation (60) and inflammation resulting in 
NFkappa mediated PR repression (61). 
In this short review, the authors have reviewed 
literature data about changes in isoforms of PG 
receptors. There is a hypothesis that human 
parturition involves changes in expression of 
myometrial nPRs and that change of expression 
leads to functional progesterone withdrawal and 
start of birth. 
The main theory is so-called IST (isoform switch 
theory) (36,62), according to which, as 
mentioned above, the ratio of PR-A and PR-B is 
changed in favor of PR-A. PR-A repress PR-B 
and reduce transcription of pregnancy 
promoting genes. Increasing level of PR-A at the 
end of pregnancy occurs because of a change in 
methylation of PR-A promoter region. That 
eventually leads to pre-term contractility of the 
uterus. 
Chai et al. wanted to clarify epigenetic 
mechanisms that contribute to the control of PR 
isoform expressions in the pregnant human 
myometrium. They researched the change in 
methylation of the cPg island in promoter region 
of PRs and uncovered an epigenetic mechanism 
for elevated PR-A:PR-B expression ratio in term 
myometrium during progesterone withdrawal. 
PR-A promoter loses H3K4me3 selective 
demethylase JARIDIA, which leads to increased 
methylation of the PR-A promoter, change of its 
transcriptional activity and change of PR-A:PR-B 
ratio (63). 
In further investigations, Nadeem et al. identified 
a mechanism by which P4 action of maintaining 
the pregnancy has been withdrawn even in the 
presence of elevated levels of this hormone in 
circulation. Unliganded PR-A localize to the 
nucleus, where they paradoxically activate 
transcription of Cx43 gene through interaction 
with AP 1 heterodimers (64). Namely, during 
pregnancy, under the influence of P4, PR-B 
create a complex with transcriptional repressors 
and inhibit transcription of Cx43. In labor, as a 
result of change of PR-A:PR-B ratio, PR-A 
become unliganded and encourage expression 
of Cx43. 
A similar mechanism can be applicable on other 
labor-associated genes, such as PTGS2, OXTR, 
OXN, PTGDS and NFKB2 and some 
proinflammatory cytokines and matrix proteins. 
This study has also showed increased level of 
progesterone metabolized with 20 alpha HSD 
enzyme, which might be important for the usage 
of appropriate progesterone for therapy of 
preterm birth (59). 
Beubaker et al. showed that the repressive 
activity of PR-A and their amount in the 
myometrium are increased by pro-inflammatory 
stimulation (65). 
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Genetic variants of PRs and their influence on 
preterm birth 
Common variant in human PRs is the so-called 
PROGINS allele. It is present in some frequency 
in more than 20% of population. PROGINS 
mutation of progesterone receptors is 
extensively investigated. One of the research 
groups, Romano et al. (66), showed that it is 
characterized by a 320 bp PV/HS-1 Alu insertion 
in intron G and two-point mutations, V660L in 
exon 4 (rs1042838 SNP) and H770H (silent 
substitution) in exon 5 (rs1042839 SNP). The Alu 
element contains a half estrogen-response 
element/Sp1-binding site (Alu-ERE/Sp1), which 
acts as an in-cis intronic enhancer leading to 
increased transcription of the PROGINS allele in 
response to 17beta-estradiol. Moreover, Alu 
insertions in the human genome are frequently 
methylated. Some data indicate that the 
PROGINS-Alu does not affect gene transcription 
due to DNA methylation. However, the Alu 
element reduces the stability of the PROGINS 
transcript compared with the CP allele and does 
not generate splice variants. The amino acid 
substitution (V600L) in exon 4 leads to 
differences in PR phosphorylation and 
degradation in the two PR variants upon ligand 
binding, likely because of differences in the 
three-dimensional structures of the two PR 
variants. Consequently, the PR-L660 (PROGINS) 
variant displays decreased transactivation 
activity in a luciferase reporter system and is less 
efficient in opposing cell proliferation in hamster 
ovarian cells expressing human PR-A, when 
compared with the PR-V660 (most common 
variant). 
PROGINS variant of PR is less responsive to 
progestin compared with the most common PR 
because of reduced amounts of gene transcript 
and decreased protein activity (66). 
It has been proven that PROGINS allele has its 
influence, and represents a risk factor in some 
patients with breast cancer, endometrial cancer 
and endometriosis. In pregnancy, we see its 
influence either in decreased effectiveness of 
PGRs on P4 or through increased risk for 
conditions associated with preterm birth.   
Another SNP that the authors wanted to 
emphasize is +331 G/A SNP of PR, which is a 
newly described mutation. Its significance lies in 
its influence on PR-A/PR-B isoform ratio, more 
specifically, its ability to change the ratio in favor 
of PR-A. The possible significance of these 
mutations could be decreased transcriptional 
regulation of progesterone target genes, which 
leads to change of pathways and start of 
preterm birth. 
Several studies have tried to show whether 
there is an influence of these four SNPs on 
modulation of preterm birth. Results are biased. 
Some studies (Diaz Cueto et al., 2008; Guoyang 
et al., 2008; Kurtz et al., 2001; Oliveira et al., 2011) 
(67,68,69,70) did not find any connection 
between polymorphism of PGR and risk of 
preterm birth. On the other hand, some studies 
(Langmia et al., 2015; Ehn et al., 2007; Tiwari et al., 
2014; Mann et al., 2013) (71,72,73,74) have found 
that mutations of PGRs have a significant 
influence on modulation of preterm birth. There 
is a possibility that either mutation in the 
mother’s or in fetal PGR genes leads to a 
difference and, consequently, preterm birth. Ehn 
at al. found that mutation in both fetal and 
maternal PRGs contributes to greater possibility 
of preterm birth. In addition, it has been proven 
that these mutations of PGR receptors 
differently influence preterm birth depending on 
race. This influence is bigger in the African-
American population. Other studies have only 
confirmed that women with these mutations 
have a greater risk of preterm birth. 
Progesterone as therapy for prevention of preterm 
birth 
Supplement of progesterone as prevention of 
preterm birth appears to be effective, but it has 
to be kept in mind that it is not an ideal medicine. 
Usage of progesterone as therapy for 
prevention of preterm birth depends on various 
factors. First of all, it is important to use the 
appropriate type of progesterone and to choose 
appropriate patients. It is also important to use a 
proper dose, route of delivery and plasma 
concentration (76,77). The pathway leading to 
preterm birth is also of importance (78,79). 
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Studies have shown that clinical efficacy and 
safety of progesterone therapy can also be 
altered due to gene polymorphisms of PGRs (75). 
That fact is especially important in the African-
American population, where genetic mutations 
of PGRs occur more often, and lead to resistance 
to progesterone therapy. 
There are two major preparations of 
progesterone used in premature birth 
therapy/prophylaxis; hydroxyprogesterone 
caproate, a synthetic progesterone usually used 
in 250 mg dosage once a week, given as an 
intramuscular injection; and natural/micronized 
progesterone in a dosage of 100 mg per day, 
given vaginally. 
There is also a rare application of progesterone 
as vaginal gel in a dosage of 90-200 mg. 
Most common usage of progesterone 
preparations as prophylaxis of preterm birth 
starts from 16-20 weeks and lasts until the 36th 
week of gestation. 
Several meta-analyses and studies have been 
made about the efficiency of progesterone 
treatment in preterm birth. 
Table 3. Recommendations for progesterone supplementation to prevent preterm birth (85). 
Progesterone preparation Dosage and route of administration Indications 
Hydroxyprogesterone caproate 
a 250 mg 
250 mg intramuscularly once a week 
from between 16th and 20th week of 
gestation until the 36th week of gestation 
Singleton pregnancy, prior 
spontaneous singleton preterm 
birth, normal cervix length. 
Singleton pregnancy, prior 
spontaneous preterm birth of 
twins, normal cervix length. 
Twins, prior preterm birth. 
Natural progesterone Vaginally  Singleton pregnancy, prior 
spontaneous singleton preterm 
birth, normal cervix length. 
Singleton pregnancy, prior 
spontaneous preterm birth of 
twins, normal cervix length. 
Twins, prior preterm birth. 
Twins, short cervix. 
Micronized progesterone  
vaginal gel/vaginal tablet 
90 mg /100 mg per day, vaginally Singleton pregnancy,prior 
spontaneous preterm birth of 
twins, short cervix < 20 mm. 
Progesterone suppository 90-200 mg per day, vaginally, from the 
moment of diagnosis until the 36th week 
of gestation 
Singleton pregnancy, prior 
spontaneous preterm birth of 
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Dodd et al. conducted a meta-analysis of usage 
of progesterone for prevention of preterm birth 
in singleton pregnant women with high risk for 
preterm birth. Usage of progesterone made the 
risk for preterm birth in their current pregnancies 
lower. (80) 
Meis et al. researched the usage of 17 
hydroxyprogesterone caproate in women who 
had a documented preterm singleton birth in 
their obstetric anamnesis. Therapy started 
between 16th and 20th week of gestation and 
was used until the 36th week. Prophylaxis 
reduced the risk of preterm birth in their current 
pregnancy. (81) 
Da Fonseca et al.  analyzed the use of 
progesterone vaginal suppository between 24th 
and 34th week of gestation. Therapy was given 
to singleton pregnant women with risk factors in 
their anamneses. Risk of preterm birth in their 
current pregnancies was reduced with 
prophylaxis. (82) 
Contrary to those findings, OPPTIMUM trial, led 
by Norman et al., showed that vaginal 
progesterone therapy did not reduce fetal and 
neonatal mortality and morbidity in preterm 
birth, or preterm birth itself. (83) 
PROGRESS study, led by Crowther et al., also did 
not find any reduction in mortality or morbidity 
of fetuses or mothers related to preterm birth 
(84). 
Conclusion 
In conclusion, usage of progesterone in 
prophylaxis of preterm birth is still indicated and 
used worldwide. The most important thing is to 
choose the right candidates with the right risk 
factors for preterm birth. Recommendations for 
usage of progesterone for prevention of preterm 
birth are given in Table 3 (85).  
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